Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10221737 | The Spine Journal | 2018 | 38 Pages |
Abstract
Endothelin-1 can reduce levels of collagen II, aggrecan, and SOX9 in CECs through activation of the Wnt/β-catenin signaling pathway, whereas BQ-123 attenuates these negative effects, highlighting a new molecular mechanism with potential for exploitation for treatment of CEP degeneration.
Related Topics
Health Sciences
Medicine and Dentistry
Orthopedics, Sports Medicine and Rehabilitation
Authors
Wei PhD, MD, Zhen-Xi PhD, Cheng-Long MD, Tian-Hui MS, Si-Wang MD, Wei-Bo MD, Feng-Lai PhD, Jian-Ru PhD, MD,